ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

EarningsCortrophinNegative

AI Analysis

Summary

Anip Therapeutics topped Q2 earnings expectations but reduced Cortrophin sales guidance, causing stock decline. The company reported better-than-expected quarterly results despite the outlook downward revision.

Financial Highlights

Guidance

Cortrophin sales guidance reduced

Importance:3/10

Sentiment:

-0.40

earningsguidance_reductionsales_concern

Related Companies

$LQDA

Read the original article

Published by yahoo_finance on August 10, 2026 5:05 PM

Read Original